Abstract Poster Wall

2024 Kidney Cancer Research Summit

Abstract 3

Genotype-phenotype associations in Von-Hippel Lindau Syndrome: implications for screening

Nicole Murray MD, MPH, MBA

Abstract 6

Durable response to immunotherapy-based regimens for IMDC favorable risk patients with metastatic clear cell renal cell carcinoma: a pooled analysis of four published randomized control phase 3 trial

Albert Jang MD

Abstract 8

Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial

Michael B Atkins MD

Abstract 9

Delving into molecular underpinnings of sarcomatoid/rhabdoid dedifferentioation in renal cancers using spatial profiling

Yasser Riazalhosseini PhD

Abstract 16

Linking VHL and SETD2 in a common oncogenic pathway that converges on the mitoticspindl

Ruhee Dere PhD

Abstract 18

Unraveling the Impact of Tumor Microenvironment on Immunotherapy Response/Resistance in Human Sarcomatoid Clear Cell Renal Cell Carcinoma: Insights from a Novel Mouse Model

Hui Jiang PhD

Abstract 21

Unconventional mechanisms of action and resistance to rapalogs in renal cancer

Ramesh Butti PhD

Abstract 23

Pre-surgical visceral adipose tissue may be a novel pre-surgical risk factor for acute kidney injury among clear cell renal cell cancer patients undergoing radical nephrectomy

Alejandro Sanchez MD

Abstract 24

Applying genomic analysis to refine unclassified renal cell carcinoma

Emre Yekeduz

Abstract 26

Applying single cell RNA sequencing of sarcomatoid renal cell carcinoma for the development of a novel transcriptomic biomarker to predict immunotherapy response

Nicholas Salgia BSc

Abstract 27

Spatial Clustering of Immunosuppressive Macrophages in Papillary Renal Cell Carcinoma

Alex Soupir PhD

Abstract 30

Synergistic systematic analysis with fully human tissue models and in silico modeling of “copycats” reveals mechanisms of T cell suppression in clear cell renal cell carcinoma

Xin-Wen Zhang MD

Abstract 35

Efficacy of treatments post-lenvatinib in patients with advanced renal cell carcinoma (aRCC)

Caiwei Zhong, MS

Abstract 36

Real-world treatment patterns and clinical outcomes of metastatic renal cell carcinoma patients post
immune-oncology (IO) and Vascular Endothelial Growth Factor (VEGF) receptor targeted therapies

Neil Shah MD

Abstract 37

Cost-effectiveness of treatment sequences with front-line nivolumab+ipilimumab therapy vs immuno-oncology+ tyrosine kinase inhibitor therapies in intermediate/poor-risk metastatic renal cell carcinoma

Hedyeh Ebrahimi

Abstract 40

Preclinical evaluation of a novel dendritic cell vaccine for kidney cancer

David Gau PhD

Abstract 43

Epigenomic profiling of translocation renal cell carcinoma via liquid biopsy

Simon Garinet PharmD/PhD

Abstract 46

Radiological tumor burden is an independent risk factor for survival in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated with first line immunotherapy (IO)-based regimens

Rashad Nawfal MD

Abstract 47

Generation and Characterization of Ex Vivo Expanded Tumor-Infiltrating Lymphocytes from Renal Cell Carcinoma Tumors for Adoptive Cell Therapy

David Einstein

Abstract 49

Inhibition of AXL along with c-Met potentially halts resistance development in renal cell carcinoma

Marc Machaalani MD

Abstract 50

National trends in the surgical management of renal cell carcinoma in Germany 

Clara Steiner

Abstract 51

Epigenetic regulation of ribosomal RNA transcription and processing by the tumor suppressor SETD2

Frank Mason, PhD

Abstract 53

Associations between body composition, ClearCode34, and clinical outcomes in localized clear cell renal cell carcinoma

Linnea Olsson PhD

Abstract 54

MicroRNA Signatures in Clear Cell Renal Cell Carcinoma: Exploring Potential Implications for Prognosis

Minghui Zhang MHS

Abstract 55

Influence of gender on immunosurveillance in a novel mouse model of clear cell renal cell carcinoma

Doris Zheng BS, MBA

Abstract 56

Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship Confirms Best-in-class Potential of Casdatifan (AB521), a Small Molecule Inhibitor of HIF-2α Being Developed in Renal Cancer

Mohammad Ghasemi PhD

Abstract 58

Tumor immune microenvironment determinants of response to Lenvatinib and aPD-1 blockade in clear cell renal cell carcinoma

Lynda Vuong PhD

Abstract 59

Risk Factors of Immune Related Adverse Events in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Razane El Hajj Chehade MD

Abstract 60

Dissecting the Cellular and Epigenetic Landscape of Clear Cell Renal Cell Carcinoma Through Paired snRNA/ATAC-Seq Analysis

Ian Gingerich BS

Abstract 62

Prognostic biomarker development using deep learning and spatial proteomics in papillary renal cell carcinoma

Jared Brewer PhD

Abstract 67

Preclinical evaluation of PSMA-based 68Ga-/225Ac-labeled radiotheranostic pair in a syngeneic mouse model of renal cell carcinoma

Anand Thotakura

Abstract 68

Use of artificial intelligence to derive International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) elements from unstructured medical records

Salvador Jaime-Casas MD

Abstract 69

Adherence to the ASCO Language of Respect guidelines in renal cell carcinoma abstracts in an international oncology meeting

Jaya Goud

Abstract 70

Circulating leptin and immune-related transcriptomic patterns in clear cell renal cell carcinoma

Lina Posada Calderon MD

Abstract 71

Exploring DNA-methylation and DNA-hydroxymethylation in clear cell renal cell carcinoma using Dirichlet multinomial regression

Yiping Li

Abstract 72

Impact of microbiome modulation on serum cytokine profile in a randomized, phase I trial of cabozantinib/nivolumab (cabo/nivo) with or without CBM588 in pts with metastatic renal cell carcinoma (mRCC)

Yu Jun Li

Abstract 74

Unraveling the Complexities of Obesity in Clear Cell Renal Cell Carcinoma Carcinogenesis

Olivia Rodriguez MS

TIPs Posters

Abstract 2

Advanced Renal Cell Cancer Combination Immunotherapy Clinical Trial (ARCITECT; HCRN GU 22-587)

Michael Serzan MD

Abstract 5

A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605

Rana R McKay MD

Abstract 19

Phase II Trial of Ubamatamab in MUC16-Expressing SMARCB1-Deficient Renal Medullary Carcinoma and Epithelioid Sarcoma

Pavlos Msaouel MD, PhD

Abstract 29

Pilot study of an implantable microdevice for in vivo evaluation of drug response in renal cell carcinoma (NCT05700461)

Wenxin Xu MD

Abstract 45

INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinoma

Toni K Choueiri MD

Abstract 75

WIRE: Window of Opportunity Clinical Trials Platform for Evaluation of Novel Treatments Strategies in Renal Cell Cancer

Grant Stewart MD, PhD

Abstract 10

RCC Clinico-Genomics Consortium: A database of linked clinical data and molecular alterations in RCC patients receiving with immunotherapy-based treatments

Jeffrey Zhong

Abstract 15

Molecular Residual Disease (MRD) Guided Adjuvant Therapy in Rental Cell Carcinoma (RCC) -MRD Gate RCC

Arnab Basu MD, MPH

Abstract 28

A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in renal cell carcinoma patients with brain metastasis previously treated with immune checkpoint blockade

Elshad Hasanov MD, PhD

Abstract 31

Multiplexed Quantification of Urinary Biomarkers for Non-invasive Classification of Imaged Kidney Tumors

Jeremiah Morrissey PhD

Abstract 33

Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC)

Regina Barragan-Carrillo MD

Abstract 65

Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Patients with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer

Gabriela Bravo Montenero MD

Abstract 66

Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

Gabriela Bravo Montenegro MD

Abstract 76

SWOG S2200 (PAPMET2): A phase II randomized trial of cabozantinib (cabo) with or without atezolizumab (atezo) in patients with advanced papillary renal cell carcinoma (PRCC)

Benjamin Maughan MD, PharmD


Kidney Cancer Research Summit

July 11–12, 2024 – Boston, MA

Click the image above to download the Abstract Book.
Updated 06.27.24